Literature DB >> 12535303

Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.

Susan I O'Shea1, Thomas L Ortel, Eugene C Kovalik.   

Abstract

Dialysis patients who are continually exposed to heparin are at risk for heparin-induced thrombocytopenia (HIT). Heparin-induced antibodies have been reported to occur in 0-12% of hemodialysis (HD) patients. The diagnosis or suspicion of HIT in this patient population requires careful confirmation of the diagnosis and substitution of heparin with an alternate anticoagulant for dialysis. Alternate agents such as the direct thrombin inhibitors (hirudin and argatroban) are available, but careful dosing and monitoring of the anticoagulant effect are required. Despite careful dosing, hemorrhagic complications have occurred with these agents. Unfortunately there are limited options for treatment of hemorrhagic complications and no specific antidotes are available for the direct thrombin inhibitors. In this report the currently available alternatives to heparin for dialysis, including dosing and monitoring recommendations, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12535303     DOI: 10.1046/j.1525-139x.2003.03014.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  10 in total

1.  Ionic liquid-derived blood-compatible composite membranes for kidney dialysis.

Authors:  Saravanababu Murugesan; Shaker Mousa; Aravind Vijayaraghavan; Pulickel M Ajayan; Robert J Linhardt
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2006-11       Impact factor: 3.368

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

3.  Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.

Authors:  Louis M Guzzi; David A McCollum; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 4.  [Argatroban: pharmacological properties and anaesthesiological aspects].

Authors:  S Kleinschmidt; B Stephan; G Pindur; C Bauer
Journal:  Anaesthesist       Date:  2006-04       Impact factor: 1.041

Review 5.  Heparin-induced thrombocytopenia: a renal perspective.

Authors:  Samaha Syed; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

6.  Impact of renal function on argatroban therapy during percutaneous coronary intervention.

Authors:  Marcie J Hursting; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

7.  Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.

Authors:  Bernd Saugel; Veit Phillip; Georg Moessmer; Roland M Schmid; Wolfgang Huber
Journal:  Crit Care       Date:  2010-05-20       Impact factor: 9.097

8.  Section 5: Dialysis Interventions for Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

9.  Effects of Citrate Acid Concentrate on Hemodialysis Adequacy, Reuse, and Quality of Life: A Prospective Randomized Crossover Trial.

Authors:  S P Nagaraju; S Kosuru; R Parthasarathy; A S Mareddy; R P Attur; D Rangaswamy; S Prasad; S Kaza; S Shenoy; K Saraf; S L K Laxminarayana; U V Mateti; V Guddattu
Journal:  Indian J Nephrol       Date:  2018 Jul-Aug

Review 10.  Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2).

Authors:  Norbert Lameire; John A Kellum
Journal:  Crit Care       Date:  2013-02-04       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.